Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma

This long-term extension study of mepolizumab in patients with severe eosinophilic asthma (exposure ≤4.5 years) identified no new safety concerns. Safety, immunogenicity, and efficacy profiles were durable and similar to previous, placebo-controlled clinical trials. (Source: Journal of Allergy and Clinical Immunology)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2NWEJEn